The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

India drug IP laws in spotlight again in local Fresenius Kabi-Pfizer case

India's policy regarding intellectual property protection has bounced back once again to deny an MNC patent challenged by a local drugmaker. This one was filed by the local unit of Fresenius Kabi Oncology against a Pfizer patent.

Relax, J&J--Eliquis may be surging, but Xarelto's safe for now

Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.

Should Eliquis' surge make Xarelto fans very, very afraid? Not really, analyst says

Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.

Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS

The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.

UPDATED: Pfizer gets friendly backing in appeal over blind rep's bid for paid driver

In the department of employee lawsuits, Pfizer is the latest drugmaker in the hot seat. But the seat is hotter for the visually impaired sales rep who sued because the company wouldn't provide a driver to ferry her to doctors' offices.

Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom

When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.

Biogen's hot MS meds could push Pfizer off its CNS throne

Pfizer is still king of the CNS hill, bringing in sales that top its Big Pharma rivals. But the company could soon face some competition at the top, as Biogen moves in with promising sales for its multiple sclerosis drugs, according to a report from GlobalData prepared for PMLiVE.

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to buy the biotech. And there's another $512.5 million on the table should Pfizer exercise its option, with the deal hinging on the biotech's successful completion of a Phase II study of a new treatment for acute kidney injury (AKI) related to sepsis.

Pfizer's early bird Ibrance making the most of its head start, execs say

If the early bird catches the worm, then Pfizer's breast cancer drug Ibrance--which won a quick approval more than two months ahead of the FDA's decision date--should be feasting. And according to company execs, it is.

Pfizer, 23andMe start building 5,000-person lupus database

Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.